前和后带皮层的GABA水平下降与轻度认知障碍中的执行功能障碍有关
Xiaona Fu1,2, Mengting Qin3, Xiaoming Liu1,2
1Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Frontiers in neuroscience
|August 28, 2023
概括
前和后带皮质中的玛-氨基黄油酸 (GABA) 减少与轻度认知障碍 (MCI) 中的执行功能缺陷有关. 较低的GABA水平可能作为MCI相关认知衰退的早期诊断标志物.
科学领域:
- 神经科学是一个神经科学.
- 认知科学 认知科学
- 医疗成像医学成像
背景情况:
- 轻度认知障碍 (MCI) 的特点是执行功能缺陷.
- 胺黄油酸 (GABA) 水平和大脑皮层厚度与认知功能有关.
- 在MCI中,GABA,皮质厚度和执行功能之间的确切关系尚不清楚.
研究的目的:
- 为了研究GABA水平,皮质厚度和MCI患者的执行功能之间的相互关系.
- 探索GABA作为生物标志物的潜力,用于早期检测MCI认知衰退.
主要方法:
- 研究了33名MCI患者和35名健康对照 (HC).
- 使用MEGA-PRESSMRI测量GABA+/肌肉蛋白 (Cr) 和谷氨酸-谷氨酸/肌肉蛋白在前环状皮质 (ACC) 和后环状皮质 (PCC) 中.
- 通过神经心理测试评估皮质厚度和执行功能.
主要成果:
- 与HC相比,MCI患者在ACC和PCC中表现出较低的GABA+/Cr水平.
- 在ACC中的GABA+和Glx水平和PCC中的GABA+水平的结合显示出MCI的高诊断准确性 (AUC:0.82).
- 在MCI中较低的GABA+/Cr水平与执行功能测试 (数字跨度向后,Trail Making Test-B) 的表现较差相关;皮质厚度没有显著的关联.
结论:
- 在ACC和PCC中降低GABA水平对MCI的执行功能障碍具有关键作用.
- 在ACC和PCC中的GABA代表了早期诊断MCI执行功能下降的有希望的潜在生物标志物.
更多相关视频
07:30Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
Published on: August 18, 2020
6.7K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.0K
相关概念视频
01:14Role of Cerebellum and Prefrontal Cortex in Memory
472
The cerebellum, while traditionally associated with motor control, also plays a crucial role in memory, particularly in procedural memory, which involves learning motor tasks that become automatic through repetition. For example, studies have shown that when the cerebellum is damaged, individuals or animals lose the ability to learn conditioned motor responses, such as the conditioned eye-blink response in classical conditioning experiments with rabbits. This study demonstrates the...
472
01:26Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
151
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
151
01:21Association Areas of the Cortex
5.5K
Association areas are regions of the cerebral cortex that do not have a specific sensory or motor function. Instead, they integrate and interpret information from various sources to enable higher cognitive processes such as memory, learning, and decision-making. Some key association areas include the following:
Prefrontal Association Area: This area is located in the frontal lobe and is involved in planning, decision-making, and moderating social behavior. It connects with primary motor areas,...
Prefrontal Association Area: This area is located in the frontal lobe and is involved in planning, decision-making, and moderating social behavior. It connects with primary motor areas,...
5.5K